SANXING(SH:601567)2023-04-26 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 2,248,372,445.81, representing a year-on-year increase of 13.42%[4] - The net profit attributable to shareholders for Q1 2023 was CNY 269,516,681.64, reflecting a significant increase of 63.84% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 265,681,678.26, up by 31.68% year-on-year[4] - The basic and diluted earnings per share for Q1 2023 were both CNY 0.19, an increase of 58.33% compared to the previous year[4] - The weighted average return on equity increased by 1.01 percentage points to 2.79%[4] - Total operating revenue for Q1 2023 reached CNY 2,248,372,445.81, an increase of 13.4% compared to CNY 1,982,418,083.43 in Q1 2022[18] - Total operating costs for Q1 2023 were CNY 1,942,265,271.77, up from CNY 1,771,349,767.48 in Q1 2022, reflecting a year-over-year increase of 9.6%[19] - Net profit for Q1 2023 was CNY 272,609,567.16, compared to CNY 169,697,089.00 in Q1 2022, representing a growth of 60.6%[20] - Earnings per share for Q1 2023 were CNY 0.19, an increase from CNY 0.12 in Q1 2022[20] - The company reported a total comprehensive income of CNY 286,068,051.13 for Q1 2023, compared to CNY 165,454,901.35 in Q1 2022[20] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 16,283,942,244.29, a slight increase of 0.35% from the end of the previous year[5] - The equity attributable to shareholders increased by 2.96% to CNY 9,787,196,127.43 compared to the end of the previous year[5] - Total liabilities decreased from approximately 16.228 billion RMB at the end of 2022 to 16.284 billion RMB as of March 31, 2023[17] - The company's total liabilities amounted to CNY 6,351,886,547.94, a decrease from CNY 6,605,796,858.33 in the previous year[18] - The total equity attributable to shareholders reached CNY 9,787,196,127.43, up from CNY 9,505,536,761.16 year-over-year[18] - The total assets increased to ¥11,807,323,967.10 from ¥11,480,186,220.60, reflecting a growth of 2.8%[26] - The total liabilities rose to ¥5,214,583,701.41, up from ¥5,031,260,300.74, indicating a 3.6% increase[26] - The company's equity increased to ¥6,592,740,265.69, compared to ¥6,448,925,919.86, marking a growth of 2.2%[26] Cash Flow - The company reported a net cash flow from operating activities of CNY 246,430,917.01, with no year-on-year comparison available[4] - The net cash flow from operating activities for Q1 2023 was ¥246,430,917.01, a significant improvement compared to a net outflow of ¥319,720,493.05 in Q1 2022[22] - Total cash inflow from operating activities reached ¥2,550,337,848.75, up from ¥1,701,437,510.63 in the same period last year, indicating a growth of approximately 50%[22] - Cash outflow from operating activities was ¥2,303,906,931.74, compared to ¥2,021,158,003.68 in Q1 2022, reflecting an increase of about 14%[22] - The net cash flow from investing activities was ¥19,937,369.33, a decrease from ¥170,854,544.09 in Q1 2022[23] - Cash inflow from financing activities totaled ¥349,771,365.48, down from ¥1,513,759,201.90 in the previous year, representing a decline of approximately 77%[23] - The net cash flow from financing activities showed a negative balance of ¥91,114,391.87, compared to a negative ¥379,678,190.29 in Q1 2022[23] - The total cash and cash equivalents at the end of Q1 2023 were ¥2,695,907,715.54, an increase from ¥2,128,006,127.97 at the end of Q1 2022[23] Operational Highlights - The company reported a total order backlog of 9.736 billion RMB as of Q1 2023, representing a year-over-year increase of 31.31%[14] - Domestic order backlog reached 5.851 billion RMB, up 17.55% year-over-year, while overseas order backlog was 3.885 billion RMB, showing a significant growth of 59.42%[14] - The company is focusing on expanding its market presence and enhancing its product offerings through new technologies and strategies[14] Expenses - The company’s management expenses increased by 45.86% primarily due to the merger of five rehabilitation hospitals and the establishment of new hospitals[10] - Research and development expenses for Q1 2023 totaled CNY 79,357,579.39, up from CNY 66,944,342.94 in Q1 2022, indicating a 18.5% increase[19] - Research and development expenses for Q1 2023 were ¥18,672,699.63, up from ¥14,999,438.49, reflecting a 24.0% increase year-over-year[27] - The company's financial expenses for Q1 2023 were CNY 1,061,995.80, compared to a gain of CNY 21,973,639.76 in Q1 2022[19]